Galapagos (GLPG) Expected to Announce Earnings on Friday

Galapagos (NASDAQ:GLPG) is anticipated to release its earnings data after the market closes on Friday, February 28th. Analysts expect Galapagos to post earnings of ($0.24) per share and revenue of $73.08 million for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Galapagos Trading Down 0.4 %

NASDAQ GLPG opened at $26.40 on Thursday. The business’s 50 day moving average is $25.39 and its two-hundred day moving average is $27.09. Galapagos has a 12-month low of $22.36 and a 12-month high of $37.22.

Analyst Ratings Changes

A number of brokerages have weighed in on GLPG. Morgan Stanley lowered Galapagos from an “equal weight” rating to an “underweight” rating and reduced their price target for the stock from $31.00 to $22.00 in a research note on Friday, February 14th. TD Cowen downgraded Galapagos from a “strong-buy” rating to a “strong sell” rating in a report on Thursday, January 9th. Barclays restated an “underweight” rating on shares of Galapagos in a research note on Thursday, January 23rd. Kepler Capital Markets cut shares of Galapagos from a “hold” rating to a “reduce” rating in a research report on Wednesday, November 20th. Finally, Royal Bank of Canada cut their target price on shares of Galapagos from $32.00 to $30.00 and set a “sector perform” rating on the stock in a report on Friday, November 1st. Five investment analysts have rated the stock with a sell rating and five have assigned a hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $26.75.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.